180 Life Sciences’ (ATNF) Sell (E+) Rating Reaffirmed at Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of 180 Life Sciences (NASDAQ:ATNF) in a research note issued to investors on Saturday,Weiss Ratings reports.

180 Life Sciences Price Performance

Shares of 180 Life Sciences stock opened at $1.56 on Friday. The company’s fifty day simple moving average is $2.10 and its two-hundred day simple moving average is $2.24. 180 Life Sciences has a 12-month low of $1.16 and a 12-month high of $17.75.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.